News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
INSYS Therapeutics Files to Withdraw IPO Plans
September 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, Sept 8 (Reuters) - U.S. biopharmaceutical company Insys Therapeutics Inc filed to withdraw its plans for an $86.3 million initial public offering, citing market conditions.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Mergers & acquisitions
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
April 6, 2026
·
2 min read
·
Tristan Manalac
Neurodegenerative diseases
Takeda Breaks Up With Denali, Dumps Dementia Drug
April 6, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts
April 3, 2026
·
3 min read
·
Annalee Armstrong
Podcast
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
April 1, 2026
·
1 min read
·
Heather McKenzie
